Brexucabtagene car pos t
Full descriptor
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Details
- Code
- Q2053
- Short descriptor
- Brexucabtagene car pos t
- Code set
- HCPCS Level II
- Release
- July 2026
- Status
- Active
- Added
- Apr 1 2021
Nearby codes
Code sets are published in blocks, so neighbours are usually related.
Home ivig, services/supplies
Lisocabtagene mara car pos t
Idecabtagene vicleucel car
Ciltacabtagene car-pos t
Doxorubicin inj 10mg
Afamitresgene autoleucel
Imported lipodox inj
Obecbtge autol up to 400 mil
Sources
- CMS HCPCS Level II — July 2026, public domain
Reference information only. Not billing advice. Verify against the payer before you file.